A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

Ira Winer,Anthony F. Shields,Oladapo Yeku,Joyce F. Liu,Mary Jane Peterman,Suk-Young Yoo,Israel Lowy,N. Alice Yama-Dang,Priscila Hermont Goncalves,Glenn Kroog

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

2021

Ira Winer
Anthony F. Shields
Oladapo Yeku
Joyce F. Liu
Mary Jane Peterman
Suk-Young Yoo
Israel Lowy
N. Alice Yama-Dang
Priscila Hermont Goncalves
Glenn Kroog

TPS5602Background: There is a high unmet need in rOVCA treatment, with 14,000 deaths/year in the US and a 30%‒40% 5-year overall survival rate in patients (pts) with advanced disease. REGN5668 and ...

Keywords:

Medicine
CD28
open label study
Recurrent Ovarian Cancer
Internal medicine
Oncology
phase i ii
Mucin
bispecific antibody
CD3
programmed death

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations